Related Experiment Video
Updated: Jun 10, 2026
04:22
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Hepatic resection for colorectal liver metastases
Russell E Brown1, Matthew R Bower, Robert C G Martin
1Division of Surgical Oncology, Department of Surgery, James Graham Brown Cancer, University of Louisville School of Medicine, 315 East Broadway, Louisville, KY 40202, USA.
The Surgical Clinics of North America
|July 20, 2010
Summary
Colorectal liver metastases (CLM) are a major cause of cancer death. Aggressive multimodality therapy offers extended survival and improved quality of life for patients with liver-dominant CLM.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Colorectal adenocarcinoma is a leading cause of cancer mortality in the US.
- Liver metastases significantly impact patient survival in colorectal cancer.
- Colorectal liver metastases (CLM) affect up to 50% of patients during their disease course.
Purpose of the Study:
- To emphasize the critical need for effective therapies for CLM.
- To highlight the benefits of multimodality treatment for CLM.
Main Methods:
- This study reviews existing data on CLM prevalence and treatment outcomes.
- Focus is on the impact of multimodality therapy on survival and quality of life.
Main Results:
- CLM is a primary determinant of survival in colorectal cancer.
- Multimodality therapy can lead to extended survival for patients with liver-dominant CLM.
Conclusions:
- Safe and aggressive multimodality therapy is crucial for managing CLM.
- Effective treatment can improve both survival and quality of life for patients with CLM.
